A series of 4,5-disubstituted cis-pyrrolidinones was investigated as inhibitors of 17beta-HSD II for the treatment of osteoporosis. Biochemical data for several compounds are given. Compound 42 was selected as the lead candidate.
4,5-Disubstituted cis-pyrrolidinones were investigated as inhibitors of type II 17beta-hydroxysteroid dehydrogenase (17beta-HSD). Early structure-activity relationship patterns for this class of compounds are discussed.
The utilization of the thiomethyl group to activate an aromatic ring system for closure to form the corresponding conformationally restrained 8-methoxy-7-(methylthio)-3-methyl-1-(spiro-1′-indan)2,3,4,5-tetrahydro-1H-3-benzazepine is described. Subsequent removal of the thiomethyl group with Raney nickel followed by electrophilic substitution allows for the synthesis of other benzazepines that have electron withdrawing groups that normally would be inaccessible.